In vivo, the relevance of a peptide targeting NRP-1 overexpressed by angiogenic endothelial cells to detect the peripheral infiltrative part of the high-grade brain tumor has been clearly demonstrated; over the past ten years, we have demonstrated the interest of vascular targeting via ATWLPPR, a ligand peptide of NRP-1 (recognition domain b1b2), but also its instability in vivo [17,18,19,20]. The gene discussed is NRP1; the disease is brain neoplasm.